- CODEN : IAJPBB
- issn 2349-7750
TITLE:
“DEXAMETHASONE ADJUNCTIVE STANDARD CARE IN REDUCING MORBIDITY AND MORTALITY RATE IN SEVERE COVID-19 PATIENTS: A SHORT REVIEW”
AUTHORS:
*Mehshikhes, Ruqayah K
ABSTRACT:
Introduction: Corticosteroids have been used for acute respiratory distress (ARDS) for more than 50 years. Recently, corticosteroids, specifically Dexamethasone, used in critically ill COVID-19 patients for respiratory support in which some evidence showed significant improvement in their condition’s outcome. Method: Search had been conducted until August 21, 2020 through looking for keywords, COVID-19 and dexamethasone, via PubMed, Cochrane Library, and MedRxiv. We reviewed all kinds of studies published lately from January 2020 to August 2020. Results: The preliminary findings of Recovery Trial are indicating benefits related to severe COVID-19 patients’ mortality rate and their hospitalization duration. Another study showed reduction in C- reactive protein and length of study. A Spanish trial is ongoing conducted on similar patients’ criteria to evaluate the mortality rate and hospitalization duration. Discussion: Giving Dexamethasone beside standard care showed significant results on COVID-19 mechanically ventilated patients. However, practitioners should take precaution in patient selection and patients who need Dexamethasone and patients who do not in order to prevent any adverse effects e.g. hyperglycemia and allergic reactions. Conclusion: Dexamethasone is still controversial when it comes to COVID-19 patients. Yet, it might be considered for ARDS patients with careful monitoring. We suggest more trials to prove the effect. Keywords: COVID-19, Coronavirus, Dexamethasone, ARDS, Corticosteroids
FULL TEXT
<Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
